This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
by Kinjel Shah
JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
by Kinjel Shah
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
by Sweta Killa
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
Company News for Jul 17, 2025
by Zacks Equity Research
Companies in The News Are: JNJ,GS,PGR,FHN
Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down
by Zacks Equity Research
NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +4.14% and +4.13%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Johnson & Johnson (JNJ) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +4.14% and +4.13%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
PPI Remained Unchanged
by Zacks Equity Research
PPI Remained Unchanged
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
by Zacks Equity Research
JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.
Strong Q2 Earnings, Cooling PPI Lead Pre-Markets Higher
by Mark Vickery
Headline PPI for June, month over month, reached 0.0% -- lower than the +0.2% expected and 30 bps below May.
Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?
by Zacks Equity Research
Bayer's shares are up 62.9% YTD as new drug approvals and a streamlined model fuel a sharp pharma turnaround.
Top Beauty and Cosmetics Stocks That May Drive Long-Term Growth
by Ansuiya Mohta
EL, COTY and ULTA are tapping AI, e-commerce, and clean beauty to ride the next wave of long-term industry growth.
3 Medical Stocks to Watch as Q2 Earnings Approach: ABT, JNJ, NVS
by Shaun Pruitt
The broader market's historic rebound may make it necessary to consider some defensive positions in the portfolio, and these medical stocks fit the bill ahead of their Q2 reports.
Q2 Earnings & CPI Data for June: Global Week Ahead
by John Blank
June Consumer Price Inflation (CPI) data lands for the U.S. and U.K., and GDP growth and Retail Sales numbers come out for Mainland China.
Pre-Markets in the Red to Start a Fresh Week
by Zacks Equity Research
Pre-Markets in the Red to Start a Fresh Week
Big Week of Inflation Data, Q2 Earnings Reports
by Mark Vickery
Not only do we look forward to the biggest of the Wall Street banks reporting Q2 earnings, but a whole host of economic prints, including a fresh Inflation Rate for the month of June, are expected.
Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure
by Zacks Equity Research
BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.
Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?
by Kinjel Shah
JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.
Pre-Markets Red on Trump's Tariff Threats to Canada
by Zacks Equity Research
Pre-Markets Red on Trump's Tariff Threats to Canada.
New Tariff Talk Sends Pre-Markets Off Record Highs
by Mark Vickery
President Trump announced a new +35% tariff on all Canadian goods imported to the U.S. this morning. Pre-markets are now in the red.
Bayer Wins Hormone-Free Treatment Approval for Women in the UK
by Zacks Equity Research
BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.
Unveiling Johnson & Johnson (JNJ) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
by Kinjel Shah
TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.